China-based Grand Life Sciences has entered into a partnership with compatriot firm Cali Biosciences Co., Ltd., becoming the exclusive commercialization partner for CPL-01 (ropivacaine sustained-release injection) in China. Under the agreement, Grand Life Sciences will pay Cali Biosciences an undisclosed amount of upfront and milestone payments, while Cali Biosciences will pay Grand Life Sciences market promotion service fees.
Product Profile and Innovation
Ropivacaine is an amide local anesthetic primarily used for surgical area blockade and acute postoperative analgesia. CPL-01, developed using the unique “PG Depot” innovative technology platform, allows for sustained release and single local administration, achieving long-lasting pain relief for up to 72 hours after surgery. This reduces the need for opioid drugs and eliminates the necessity for special equipment such as pain pumps, making it convenient for clinical use and reducing the burden on patients.
Clinical Data and Benefits
Phase II clinical data showed that participants treated with CPL-01 had better postoperative pain intensity scores and reduced opioid use compared to the placebo group, with good safety performance. This highlights the potential of CPL-01 to offer a more effective and convenient pain management solution for patients undergoing surgery.
Significance of the Partnership
The collaboration between Grand Life Sciences and Cali Biosciences aims to accelerate the commercialization of CPL-01 in China, providing a novel and effective treatment option for postoperative pain management. This partnership underscores the commitment of both companies to improving patient outcomes and advancing innovative medical solutions.-Fineline Info & Tech
Leave a Reply